Estrella lands $5M to fuel Timor-Leste manganese exploration push
The cash came after MJ Ratta Investments exercised the second tranche of an option subscription agreement, inked in September last year.
Subject to shareholder approval, the investor will receive 136.76 million shares at 3.656 cents per share, which is a 20 per cent discount to Estrella's 10-day volume-weighted average price of 4.57c.
The first tranche raised $350,000 from the issue of 53.3 million shares at 0.006c per share.
Estrella says the move is a major endorsement of the company's fast-moving strategy in a region that, until now, has never seen modern drilling for metallic minerals.
The new funding package boosts Estrella's balance sheet and also comes with attractive terms for Ratta. The investor will gain an increased gross revenue royalty from manganese production – up from 0.25 per cent to 0.5 per cent - and an extended royalty life from five to seven years if production gets up.
Additionally, the company has pledged a first-ranking security interest on its Spargoville nickel mineral rights until it can confirm delivery of 20,000 tonnes of ore to port.
With the blessing of local Timor-Leste communities and its nascent mining industry, Daws added that Estrella has also received staunch support from its institutional shareholders.
The funds will be used to ramp up Estrella's ongoing 3000-metre diamond and 10,000m reverse circulation drilling blitz and pave the way for a follow-up 10,000m reverse circulation campaign, subject to results.
The timing of the new cash has come at an exciting time for the company, which recently landed some big manganese results.
Last week, the drill bit struck a standout 7.76m hit of manganese oxide from just 30 centimetres below surface at its Ira Miri project in the country's northwest.
The discovery came from a diamond drill hole using an upgraded rig, which twinned the project's first hole that had earlier pulled up short in mineralisation. Fitted with an appropriate drill bit and improved drilling fluids, the rig is capable of churning through the harder material, leading to an improved core recovery.
Core visuals revealed thick, high-grade manganese zones, with some sections potentially hitting 100 per cent manganese oxide. Notably, the intercepts are already rivalling Australia's renowned Groote Eylandt deposit, which averages just 3m wide.
Estrella says the material appears to be in-situ supergene enrichment from the Noni Formation and looks extremely well preserved beneath ancient overburden.
Drilling is continuing with step-out holes to test scale and continuity at Ira Miri, while the company pushes on with its permitting efforts to ramp up exploration at its Werumata and Lautém sites, further south.
In parallel with the hunt for manganese, the company is also chasing a large limestone opportunity as part of a partnership and an offtake agreement already in place to monetise the resource.
Last month, Estrella struck a binding deal with Indonesian group PT Raka Energi Mandiri (REM) to potentially export up to 500 million tonnes of high-grade limestone from Timor-Leste across the next five years.
The agreement gives REM exclusive marketing and off-take rights and includes a performance incentive of up to 500 million share options at 5c each.
The joint venture, dubbed Estrella Murak Rai Timor Lda, will retain all revenue from limestone sales. Estrella owns 70 per cent of the joint venture with Timor-Leste's state-owned Murak Rai Timor holding the balance.
The material shows up as a clean, coral-rich layer running along the top of the dominant Baucau Formation, which stretches across the company's 195 square kilometre concession. The resource also conveniently sits above its main manganese targets, allowing for dual-resource exploration in a single drill run.
Recent assays confirmed the limestone is a premium-grade calcite with minimal impurities, making it highly sought-after for use in cement, glass and agriculture. It is also the perfect neutralising agent in nickel processing and for environmental remediation.
With strong backing from the investor, local communities and a budding Timor-Leste mining industry, Estrella appears well-positioned to continue blazing a trail through uncharted territory.
The company has already marked itself as a pioneer in the region and now, with $5 million in the bank, it appears ready to dig even deeper.
Is your ASX-listed company doing something interesting? Contact:
matt.birney@wanews.com.au
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
29 minutes ago
- Sydney Morning Herald
The big money behind childcare operator at the heart of alleged sex abuse scandal
The childcare operator at the centre of the sector's alleged sexual abuse scandal, Affinity Education, lost money last year as it continued with an acquisition binge designed to give its rich-lister backers a lucrative exit. The for-profit childcare sector at large has come under intensifying pressure following allegations that Joshua Dale Brown had allegedly sexually abused children at several Victorian centres, but the Quadrant Private Equity-owned Affinity has also been dogged by other alleged incidents. Brown's case is still being investigated and remains before the courts. Queensland Police charged a 21-year-old male employee of an Affinity centre in Brisbane on July 10 over an offence alleging indecent treatment of a child. That came as the list of centres that Brown worked at continued to balloon, including additional centres owned by Affinity. Scrutiny of Affinity has been limited compared with the ASX-listed G8 Education – which has had hundreds of millions of dollars wiped from its market capitalisation after the charges against Brown were made public – despite Affinity owning 13 of the 23 centres where Brown worked. But financial statements lodged with the corporate regulator by the Brisbane-headquartered Affinity portray a company on an expansion binge since Quadrant bought it in 2021. Financial statements lodged with ASIC show that in the 2024 calendar year, Affinity posted an after-tax loss of more than $20 million, with huge debt bills playing a significant role, despite underinvestment in staff compared with the rest of the industry. Affinity's accounts for the financial year ending December 31, 2024, show it was saddled with $614 million worth of loans, just shy of the $650 million that Quadrant paid for Affinity in 2021 when the company borrowings totalled $325 million.
The Age
29 minutes ago
- The Age
The big money behind childcare operator at the heart of alleged sex abuse scandal
The childcare operator at the centre of the sector's alleged sexual abuse scandal, Affinity Education, lost money last year as it continued with an acquisition binge designed to give its rich-lister backers a lucrative exit. The for-profit childcare sector at large has come under intensifying pressure following allegations that Joshua Dale Brown had allegedly sexually abused children at several Victorian centres, but the Quadrant Private Equity-owned Affinity has also been dogged by other alleged incidents. Brown's case is still being investigated and remains before the courts. Queensland Police charged a 21-year-old male employee of an Affinity centre in Brisbane on July 10 over an offence alleging indecent treatment of a child. That came as the list of centres that Brown worked at continued to balloon, including additional centres owned by Affinity. Scrutiny of Affinity has been limited compared with the ASX-listed G8 Education – which has had hundreds of millions of dollars wiped from its market capitalisation after the charges against Brown were made public – despite Affinity owning 13 of the 23 centres where Brown worked. But financial statements lodged with the corporate regulator by the Brisbane-headquartered Affinity portray a company on an expansion binge since Quadrant bought it in 2021. Financial statements lodged with ASIC show that in the 2024 calendar year, Affinity posted an after-tax loss of more than $20 million, with huge debt bills playing a significant role, despite underinvestment in staff compared with the rest of the industry. Affinity's accounts for the financial year ending December 31, 2024, show it was saddled with $614 million worth of loans, just shy of the $650 million that Quadrant paid for Affinity in 2021 when the company borrowings totalled $325 million.
News.com.au
5 hours ago
- News.com.au
Innovation isn't enough – why Morgans says profitability drives ASX healthcare success
Morgans' Scott Power says path to profitability is key to a successful emerging ASX health care company While innovation is important, Power says the market loses interest in companies which don't turn a profit Wound care company Aroa Biosurgery delivered its first normalised profit in FY25 since listing in 2020 What makes a successful emerging ASX healthcare company and a smart investment? It's the question with no single answer but according to the experts there are certain factors investors should look for, including combining innovative science with strong commercial potential, a path to market and profitability. Morgans' senior healthcare analyst Scott Power has been covering the ASX sector for more than 27 years. He said success isn't just about innovation, but strong sales execution and market delivery. Successful players secure clinical validation, navigate regulatory hurdles efficiently and target real, unmet needs to help not only patients but deliver returns for investors. Indeed it is this path to profitability that Power sees as crucial overarching requirement for success. "You can develop a product and put a lot of R&D into it but ultimately it needs to get to market and be sold with profits being generated if you are going to grow as a listed company," Power told Stockhead. "Our pool of funding over here is not deep enough to keep funding the next idea compared with the US where capital markets are deeper and can fund R&D right through to commercialisation. "The market loses interest in companies which continue to produce losses." Power said that in what has been a tough market for the last several years for the ASX emerging healthcare sector, having a clear path to profitability was imperative. "In the last month I have seen a turnaround in level of interest and rotation back to the sector with share prices starting to move," he said. "The companies that are profitable or have a clear path to profitability are the ones being rewarded." Case in point… Aroa delivers maiden profit for FY25 New Zealand-based soft-tissue repair company Aroa Biosurgery (ASX:ARX) surged into the black in FY25, delivering its first profit since listing on the ASX in 2020. Operating under the Kiwi financial year, which ends on March 31, Aroa reported a normalised EBITDA profit of NZ$4.2 million for FY25 – a sharp turnaround from the NZ$3.1m loss recorded in FY24. Total revenue for FY25 of NZ$84.7m was an increase of 23% on the previous year and exceeded guidance of NZ$81-84m. "For them it's a balance between how much money they want to continue to invest in R&D and how quickly they want to grow EBITDA," Power said. "Given their revenue is growing at 20% and they're holding their R&D in absolute terms stable they're getting there and could get their faster by pulling back on the R&D but then it becomes a question of how innovative do they want to remain at expense of profitability? "It is a tough question to balance because on one hand you have a bigger pool of investors, which will look at you if you're profitable and another smaller pool looking for the innovation, so the next ProMedicus (ASX:PME), Cochlear (ASX:COH) or ResMed (ASX:RMD)." Strength in innovation While the point's been made here that a strong path to profitability is critical to sustained success, Power noted Aroa's great strength lies firstly in innovation. Its products are derived from ovine forestomach matrix (sheep rumen) sourced exclusively from New Zealand. The matrix is processed and sterilised to remove DNA and cells, leaving a tissue scaffold called the ECM for new tissue to grow, which contains a dense network of vascular channels – a structure like human skin – and more than 150 proteins critical to healing. Aroa has developed several products using its ECM technology including Endoform, Myriad and Symphony – each designed to support soft tissue repair across a range of surgical and wound care applications. "They have a lot of peer-reviewed scientific studies which have been published," Power said. "Aroa's scientific know-how is very high and they have continued to innovate with new product offerings, with a strong R&D team." The company has a hybrid approach to selling its products with a direct sales force for selling Endoform, Myriad and Symphony. Hernia repair and breast reconstruction product Ovitex is manufactured by Aroa on behalf of its Nasdaq-listed business partner TELA Bio. Does the product fill an unmet need? Morgans' healthcare analyst Iain Wilkie reckons filling an unmet medical need or shortfall in existing standard of care is also important to success for an emerging ASX healthcare company. "It either needs to be better than the existing standard of care or perform the same but be cheaper," he told Stockhead. "You would probably say the easiest path to market is if it is an improvement or filling an unmet medical need." Wilkie said a good example was EBR Systems (ASX:EBR), which in April gained US Food and Drug Administration (FDA) approval for its WiSE CRT System – the world's only wireless endocardial (placed within the heart) pacing system in clinical use for stimulating the heart's left ventricle. "EBR has just started selling its WiSE and it has a very clear case of targeting an unmet medical need and fixing a problem which exists and being the only device which can do it," Wilkie said. He noted Nanosonics (ASX:NAN) was also a good example of a healthcare company addressing an unmet need in the healthcare sector. Nanosonics has been a leader in infection prevention with its flagship Trophon system – an automated ultrasound probe cleaner that uses sonically-activated hydrogen peroxide mist. Trophon has become standard of care for cleaning ultrasound probers in several countries, including Australia. In March 2025, Nanosonics received FDA de novo clearance for Coris, the world's first automated system specifically designed to clean the internal channels of flexible endoscopes. "They've already got one product which has been selling well for almost two decades and now they're launching their new product," he said. At Stockhead, we tell it like it is. While Aroa Biosurgery and EBR Systems are Stockhead advertisers, the companies did not sponsor this article.
